The secondary cancers like cutaneous squamous-cell carcinoma, skin papillomas and keratoacanthoma are considered to be the characteristic adverse events of BRAF inhibitor monotherapy, and occur in approximately 14 to 26% of the patients [30, 31]. The gene discussed is BRAF; the disease is cutaneous squamous cell carcinoma.